Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | Lima | Healthcare | Pharmaceuticals | PEN 2.78T | 39.4x | 0.42 | PEN 3,184.47 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Johnson & Johnson | Lima | Healthcare | Pharmaceuticals | PEN 1.98T | 27.3x | PEN 816.42 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
| Merck | Lima | Healthcare | Pharmaceuticals | PEN 985.02B | 16.2x | 2.03 | PEN 403.06 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Gilead Sciences | Lima | Healthcare | Pharmaceuticals | PEN 585.70B | 20.4x | 0.01 | PEN 419.93 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Pfizer | Lima | Healthcare | Pharmaceuticals | PEN 524.91B | 19.9x | -5.91 | PEN 95.91 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Bristol Myers Squibb | Lima | Healthcare | Pharmaceuticals | PEN 399.62B | 16.6x | 0.09 | PEN 199.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Regeneron Pharmaceuticals | Lima | Healthcare | Pharmaceuticals | PEN 261.50B | 18.1x | 2.08 | PEN 2,485.49 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Moderna | Lima | Healthcare | Pharmaceuticals | PEN 72.65B | -7.5x | -0.33 | PEN 171.82 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |